The pharmacological inhibition of TRAF4 by risperidone has been demonstrated to be an effective means of inhibiting tumor self-renewal in glioblastoma, with a concomitant reversal of temozolomide (TMZ) resistance (58). Here, TRAF4 is linked to neoplasm.